 |
|
|
| |
Safety and pharmacokinetics of ABI-H3733, a
novel second-generation HBV core inhibitor:
Results from a Phase 1a study in healthy volunteers
|
| |
| |
AASLD 2021 Nov 12-15
Edward Gane1, Christian Schwabe2, Katia Alves3, Marc Evanchik3, Julie Ma4, Katie Zomorodi4, Steven J Knox4, Luisa M Stamm4
1Liver Transplant Unit, University of Auckland, Auckland, New Zealand; 2New Zealand Clinical Research, New Zealand; 3Former employee of Assembly Biosciences, Inc.; 4Assembly Biosciences, Inc., South San Francisco, CA, USA
|
| |
|
|
|
|
|
